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Background: Recent studies report curcumin nanoformulation(s) based on polylactic-co-glycolic 
acid (PLGA), β-cyclodextrin, cellulose, nanogel, and dendrimers to have anticancer potential. 
However, no comparative data are currently available for the interaction of curcumin nanofor-
mulations with blood proteins and erythrocytes. The objective of this study was to examine the 
interaction of curcumin nanoformulations with cancer cells, serum proteins, and human red blood 
cells, and to assess their potential application for in vivo preclinical and clinical studies.
Methods: The cellular uptake of curcumin nanoformulations was assessed by measuring 
curcumin levels in cancer cells using ultraviolet-visible spectrophotometry. Protein interaction 
studies were conducted using particle size analysis, zeta potential, and Western blot techniques. 
Curcumin nanoformulations were incubated with human red blood cells to evaluate their acute 
toxicity and hemocompatibility.
Results: Cellular uptake of curcumin nanoformulations by cancer cells demonstrated preferential 
uptake versus free curcumin. Particle sizes and zeta potentials of curucumin nanoformulations 
were varied after human serum albumin adsorption. A remarkable capacity of the dendrimer 
curcumin nanoformulation to bind to plasma protein was observed, while the other formulations 
showed minimal binding capacity. Dendrimer curcumin nanoformulations also showed higher 
toxicity to red blood cells compared with the other curcumin nanoformulations.
Conclusion: PLGA and nanogel curcumin nanoformulations appear to be very compatible 
with erythrocytes and have low serum protein binding characteristics, which suggests that they 
may be suitable for application in the treatment of malignancy. These findings advance our 
understanding of the characteristics of curcumin nanoformulations, a necessary component in 
harnessing and implementing improved in vivo effects of curcumin.
Keywords: nanoparticle, curcumin, chemotherapy, cellular uptake, protein binding, 
hemocompatibility
Introduction
Curcumin (structure shown in Figure 1A) is a natural diphenolic compound extracted 
from the herb Curcuma longa, and is widely used in traditional Indian and Chinese 
medicine. Curcumin has numerous biological and pharmacological activities, with 
no major side effects, and is currently being used in several clinical trials for treating 
several disorders, including Alzheimer’s disease, hypercholesterolemia,   atherosclerosis, 
  psoriasis, Crohn’s disease, neurological disorders, and cancer.1,2 Recent studies estab-
lish that curcumin can be translated into a therapeutic molecule to treat a variety of 
cancers.3,4 In addition, studies have demonstrated that curcumin is an efficient molecule 
for overcoming multidrug resistance phenomena as well as inducing sensitization of 
tumor cells for chemotherapy and radiation.5–10 Unfortunately, the strong potential 
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Figure 1 structural variations of the curcumin nanoformulations and their uptake in cancer cells. (A) chemical structure of curcumin. (B) Different types of curcumin 
nanoformulations and their structures based on chemical composition. structures do not represent exact size or orientation, and the solid background is intended to 
distinguish the different formulations. Entire polymer chains, drugs (curcumin), and other structures are defined in the figure itself. (C) cellular uptake of curcumin 
nanoformulations in sKBr-3, MDA-MB-231, and hPAF-II cancer cells. cancer cells were treated with curcumin 20 µg or curcumin nanoformulations (20 µg equivalent to 
curcumin) for 6 hours. Uptake was determined by recording absorption of acetone cell lysates at λmax 450 nm using UV-vis spectrophotometer.
Notes: Data are reported as the mean of three repeats for each uptake (mean ± standard error of the mean deviation; *P , 0.05, curcumin nanoformulations versus free 
curcumin). 
Abbreviations: cD, β-cyclodextrin; cUr, curcumin; PLgA, polylactic-co-glycolic acid; PVA, polyvinyl alcohol; PLL, poly-L-lysine.
of curcumin to improve the effectiveness of cancer treat-
ment is hindered by its poor bioavailability, attributable to 
its poor aqueous solubility, degradation, and high rate of 
metabolism.11–13
Because of its hydrophobic nature and poor bioavail-
ability, the clinical development of curcumin as a “medicine” 
is dependent upon developing a nanocarrier for efficient 
transport in the body.12,14,15 Recently, several curcumin 
  nanoformulations, such as polymer nanoparticles, self-
  assemblies, nanocrystal dispersions, nanoemulsions, lipid 
nanoparticles, and protein-based drug delivery systems, 
have shown improved solubility, stability, and bioavail-
ability of the curcumin molecule.14–20 Moreover, curcumin 
nanoformulations have demonstrated improved cellular 
uptake in cancer models that increases the chance of a 
positive therapeutic outcome. Curcumin nanoformulations International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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have also exhibited superior in vitro anticancer responses 
compared with free curcumin due to sustained release of the 
active compound and the enhanced permeation and retention 
effects of nanoformulations.16,19,21,22 Several of these nano-
formulations have been successful in raising the area under 
the concentration-time curve, half-life, and mean residence 
time of curcumin in serum and in various organs.16,23–25 In 
our previous study, we describe a comparative evaluation of 
β-cyclodextrin, hydroxyl propyl methyl cellulose (cellulose), 
polylactic-co-glycolic acid (PLGA) and dendrimer curcumin 
nanoformulations with free curcumin using cytotoxicity, 
cellular uptake, and apoptosis studies in cancer cells and 
suggests a close relationship with the therapeutic efficacy of 
the formulation.26 However, there is no tool to evaluate the 
behavior of curcumin nanoformulations in vivo. Similarly, 
while a number of curcumin nanoformulations have been 
reported in the literature, so far there has been no compara-
tive study to evaluate which formulation(s) is more efficient 
for in vivo cancer therapeutics.
Preclinical properties of nanoformulations depend upon 
avoiding rapid clearance from the systemic circulation by 
the cells of the immune system.27–29 Usually, the in vivo fates 
of nanoformulations follow many potential routes before 
reaching their actual target(s).30–32 Therefore, the in vivo 
outcome of nanoformulations depends on the biological 
fluid interactions with particle surfaces where particles may 
aggregate or stabilize, or be subjected to clearance, uptake, 
and trafficking processes.33–35 Conventional nanoparticle 
formulations readily interact with plasma proteins, opsonize, 
and are taken from the blood circulation by phagocytes. 
Modification of the surface properties of nanoformulations 
remains a key feature that can enhance their half-life, which 
is likely to be predictive of therapeutic outcome. Further, 
hemocompatibility of nanoformulations is an initial check 
point in understanding their utility in vivo. Therefore, the 
aim of this study was to examine the interaction of curcumin 
nanoformulations with plasma proteins and red blood cells 
and as a result, predict the implications of their biological 
characteristics for in vivo application.
Materials and methods
Curcumin ($95% purity), β-cyclodextrin, cellulose (molecu-
lar weight 10,000, methoxy 1.8–2.0 and propylene oxide 
0.2–0.3, viscosity 2 wt% in water, 5 cps), polyvinyl alcohol 
(molecular weight 30,000–70,000), poly-L-lysine (molecular 
weight 30,000–70,000), N-isopropyl acrylamide (NIPAM), 
polyamidoamine dendrimer generation 4 (10 wt%   solution), 
sodium dodecyl sulfate, fibrinogen, immunoglobulin G, 
transferrin, human serum albumin (HSA) and acetone ($99.5, 
American Chemical Society reagent grade) were purchased 
from Sigma Chemical Co (St Louis, MO). PLGA, 50:50 
lactide-glycolide ratio, inherent viscosity 1.32 dL/g at 30°C) 
was purchased from Birmingham Polymers (Pelham, AL). All 
chemicals were used as received without further   purification. 
Ultrapure water was produced by   purification with an 
Ultrapure® water system (Elga, Woodridge, IL). Curcumin 
nanoformulations (Figure 1B) were obtained following our 
previous protocols using PLGA, β-cyclodextrin, cellulose, 
nanogel (polyNIPAM), and dendrimer through self-assembly/
complexation/redox free radical solution polymerization 
or encapsulation techniques.21,22,26,36 For consistency, all 
curcumin nanoformulations were processed with 20 wt% 
curcumin loading. A schematic representation of curcumin 
nanoformulations are provided in Figure 1B.
In vitro cellular uptake
In vitro cellular uptake studies were performed as described 
in our previous reports.21,22 MDA-MB-231, SKBR-3 
(breast), and HPAF-II (pancreatic) cancer cells (1 × 105) 
in Dulbecco’s modified Eagle’s medium or F12 medium 
were incubated in either 20 µg of free curcumin (dissolved 
in   dimethylsulfoxide) or an equivalent amount of curcumin 
nanoparticles. After 6 hours of incubation, the cells were 
washed with phosphate-buffered solution (10 mM, pH 7.4), 
trypsinized, and centrifuged at 1000 rpm. The cell pellet 
containing curcumin in cancer cells was resuspended in 1 mL 
of acetone and sonicated for 5 minutes. The lysates were 
centrifuged at 12,000 rpm for 15 minutes and the curcumin 
levels were recorded for the supernatant curcumin solution.21 
A standard plot of curcumin in acetone (1–10 µg) was pre-
pared identically to calculate curcumin uptake by the cells.
Protein adsorption
Particle size, shape, and zeta potential
The particle size, shape, and zeta potential of nanoparticles 
can vary after serum protein adsorption/interaction. To evalu-
ate this phenomenon, curcumin nanoformulations (1 mg/mL) 
were dispersed in 100 µg HSA for 2 hours at 25°C. The nano-
formulations were centrifuged at 12,000 rpm for 15 minutes 
to obtain HSA-bound nanoparticles. The particle size and 
zeta potential of HSA-bound curcumin nanoformulations 
were measured using a Delsa™ Nano C particle size analyzer 
(Beckman Coulter, Miami, FL).   Particle size and distribu-
tion was measured for 3 minutes, and the zeta potential was 
measured for 90 runs (9 minutes). The surface morphol-
ogy of curcumin formulations and   HSA-bound curcumin International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  nanoformulations was observed under a JEOL-1210 
transmission electron microscope (JEOL, Tokyo, Japan) 
operating at 80 kV. The nanoformulation samples were 
stained with uranyl acetate solution to accentuate fine struc-
tures under transmission electron microscopy.
Western blot
Curcumin nanoformulations (20 µM) were incubated in 
100 µg of various plasma protein solutions at 37°C.   During 
incubation, adsorption of proteins occurred on the nanopar-
ticle surfaces. Following 2 hours of incubation, the samples 
were centrifuged at 12,000 rpm for 15 minutes to obtain 
pellets of protein-adsorbed curcumin   nanoparticles. The 
adsorbed proteins were removed by adding an electropho-
resis sample buffer (Santa Cruz Biotechnology, Santa Cruz, 
CA) and heating to 95°C for 5 minutes. These protein 
samples were loaded in 4%–20% polyacrylamide gel and 
then underwent sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis at 150 V for 60 minutes. The gels 
were placed in 100 mL ultrapure water and microwaved 
(  Emerson® microwave oven, MW8777 W, 700 W) on high 
for 3 minutes and allowed to cool down for 5 minutes. 
After the water was discarded, 20 mL of SimplyBlue™ 
SafeStain solution (Coomassie® G-250 stain, Invitrogen, 
Carlsbad, CA) was added and the gel was microwaved on 
high for 45 seconds. The gel was allowed to cool down, 
washed with ultrapure water and incubated in 20 mL of 
20% sodium chloride solution for 5 minutes. The gels were 
scanned using a BioRad Gel Doc (BioRad, Hercules, CA) 
and the intensity quantification of bands was acquired using 
AlphaEase Fc software.10
Flow cytometry
To determine the adhesion properties of curcumin nanofor-
mulations in human red blood cells, a flow cytometric assay 
was employed. For this study, 100 µL of healthy male human 
blood (Biological Specialty Corporation, Colmar, PA) was 
incubated with 10–40 µM curcumin nanoformulations for 
2 hours in 1 mL of RPMI medium at 37°C. During incuba-
tion, the curcumin nanoformulations readily established 
interaction with plasma proteins while the free curcumin 
nanoparticles bound with red blood cells.
After incubation, the entire solution was filtered through 
a polystyrene round-bottom tube with cell-strainer cap 
and injected into an Acuri C6 Flow Cytometer (Accuri™ 
  Cytometers Inc, Ann Arbor, MI) to determine the fluo-
rescence levels of curcumin nanoformulations attached 
to red blood cells in flow channel 1 absorbance (FL1A, 
488   excitation, blue laser, 530 ± 15 nm, fluorescein 
isothiocyanate/green fluorescent protein). Red blood cells 
were first gated using side and forward scatter in the Accuri 
software and   nanocurcumin particles bound to red blood cells 
in this range only were analyzed by flow cytometry. Because 
unbound nanoparticles were way below the range, they did 
not interfere with the data.
hemolysis test
Hemolysis causes damage to red blood cells via the release 
of iron-containing protein hemoglobin into plasma. To 
evaluate curcumin nanoformulations for human use, for-
mulations must first be checked for hemolytic compatibility. 
In this study, 8 mL of whole blood from a healthy male   
was centrifuged at 2000 rpm for 10 minutes to obtain red 
blood cells, which were then resuspended in 8 mL RPMI 
1640 growth media. Different concentrations of curcumin 
nanoformulations (0–200 µM) were incubated at 37°C with 
100 µL red blood cells in Eppendorf tubes. After 2 hours 
of incubation at 37°C, the extent of hemolysis caused by 
  curcumin nanoformulations was observed macroscopi-
cally, the tubes were centrifuged, and the supernatant fluid 
was measured for optical density at λmax 570 nm using 
ultraviolet-visible spectrophotometry (BioMate 3 spectro-
photometer, Thermo Electron Corporation, Waltham, MA). 
  Phosphate-buffered solution and sodium dodecyl sulfate 
were used as the negative and positive controls,   respectively. 
To observe the visual effect of red blood cell membrane 
damage, the red blood cell pellets were redispersed in 
phosphate-buffered solution after treatment, and a drop 
of solution was placed on a glass slide for imaging using 
an Olympus BX 41 phase contrast microscope (Olympus, 
Center Valley, PA). A transmission electron microscopy 
study was performed according to our previously reported 
method to identify further nanoparticle association with 
the red blood cells.21
statistical analysis
The data were processed using Microsoft Excel 2007   software 
and presented as the mean ± standard error of the mean. 
  Statistical analyses were performed for the overall com-
parison between groups using analysis of variance   models. 
If the analysis of variance model F-test was significant at 
the 0.05 level, the difference between groups was examined 
using a pairwise t-test and each group was compared with 
the control. The analysis was performed using SAS 9.2 (SAS 
Institute, Inc, Cary, NC). All graphs were plotted using Origin 
6.1 software.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Results and discussion
Many reports confirm that nanoparticles with a size of less 
than 200 nm can be taken up by cancer cells through endo-
cytosis or diffusion.37–39 In addition to particle size, the type 
and surface characteristics of nanoformulations contribute to 
the regulation of uptake.40–42 Some nanoformulations are toxic 
due to the surfactants used in their preparation. Therefore, 
in this study we explored the feasibility of five different cur-
cumin nanoformulations for cancer therapy based on cancer 
cell uptake, as well as their interaction with human plasma 
proteins and red blood cells.
cellular uptake
First, all five curcumin nanoparticle formulations were studied 
for uptake into SKBR-3, MDA-MB-231 (breast), and HPAF-II 
(pancreatic) cancer cells to evaluate their feasibility as drug 
(curcumin) delivery vehicles. This uptake study will be useful 
to identify which curcumin nanoformulations are efficient com-
pared with free curcumin. Uptake was achieved by incubating 
the cancer cells with 20 µg of curcumin or 20 µg equivalent cur-
cumin nanoparticles for 6 hours. Curcumin uptake was deter-
mined by the absorbance measurement of acetone-extracted 
cell lysates. Preferential uptake of curcumin was observed 
in all three cancer cells by the curcumin nanoformulations in 
comparison with free curcumin (Figure 1C). This enhanced 
uptake behavior of various curcumin nanoformulations has been 
observed previously in many cancer cells.16,21,22,43–45 Curcumin 
uptake in cancer cells, in descending order, was found to be 
MDA-MB-231 . SKBR-3 . HPAF-II. Overall, the dendrimer 
curcumin formulation showed noticeably higher uptake by can-
cer cells than the PLGA, β-cyclodextrin, cellulose, and nanogel 
curcumin formulations. This significantly higher uptake could 
be due to the positive zeta potential or higher penetration 
capacity via functional amino groups on the dendrimer. These 
results suggest that nanoparticle-mediated delivery of curcumin 
is more efficient and better able to reach cancer cells than free 
curcumin, and may effectively improve therapeutics. Although 
all five curcumin nanoformulations showed enhanced uptake, 
their in vivo properties may be different, depending on several 
factors, including stability of the curcumin nanoformulations 
in the presence of blood proteins and interaction with erythro-
cytes. Therefore, we investigated interaction of blood proteins 
and erythrocytes for all five curcumin formulations.
Association of curcumin nanoparticles 
with hsA
Newly developed drug nanoformulations may have a direct 
interaction with tissues and cells after administration to 
animals and humans.46 The ability of nanoformulations to 
achieve a higher therapeutic value relies on their biocom-
patibility and lower serum protein binding capacity which, 
in turn, is important for industrialization. In general, serum 
proteins readily bind onto the surfaces of various nanopar-
ticles within one hour.47,48 Proteins adsorb on the surfaces of 
nanoparticles quickly and their characteristics may change 
before reaching the intended target(s). The degree of protein 
interaction may depend on particle size, surface stabilization, 
functional or chemical groups on the surface, and composi-
tion of the particles.48–52 Therefore, we first addressed how 
the curcumin nanoparticles surface is adsorbed by HSA. 
We chose HSA because it is the most abundant protein in 
human plasma (3.4–5.4 g/dL).
Different curcumin nanoparticles have variable par-
ticle sizes and morphology (Figure 2A, top panel). PLGA, 
β-cyclodextrin, cellulose, nanogel, and dendrimer curcumin 
nanoformulations had particle sizes of about 52, 41, 36, 
48, and 42 nm, respectively. After incubation with HSA, 
most of the nanoparticles had a similar particle size, but 
their morphology was distinctive, ie, they were either 
coated with HSA corona or showed a change in their 
aggregation behavior (Figure 2A, lower panel). This varia-
tion in the morphology of nanoparticles is similar to that 
caused by the formation of soft corona or loosely bound 
proteins on metal or polymer nanoparticle surfaces.50,53,54 
High accumulation of dark spots in the β-cyclodextrin and 
cellulose curcumin nanoformulations after HSA incuba-
tion is related to the stain (uranyl acetate, Figure 2A, red 
arrows) used to assist detection under transmission electron 
microscopy, not to actual nanoparticle aggregation. This 
may be because a higher rate of adsorption of metal ions 
to β-cyclodextrin and/or cellulose exists through an inclu-
sion complex or ionic bonding. This behavior can be seen 
in β-cyclodextrin formulation before and after incubation 
with HSA (red arrows), but not in the cellulose formulation 
before incubation with HSA. A change in the overall particle 
morphology or structure after incubation with HSA may 
occur, and thus more dark staining is present in the case of 
the cellulose nanoformulation. In the case of the dendrimer 
curcumin nanoformulation, an aligned network was seen 
throughout the sample due to the HSA layers (Figure 2A, 
blue arrows).
Since most of the HSA protein adsorption is loosely 
coated to all curcumin nanoparticle surfaces, their overall 
particle size aggregation decreased (Figure 2B). This indi-
cates that the adsorbed HSA helps to reduce particle–particle 
interaction but does not change in the individual particle International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure  2  human  serum  albumin  binding  alters  the  physicochemical  properties  of  the  curcumin  nanoformulations,  ie,  PLgA,  β-cyclodextrin,  cellulose,  nanogel,  and 
dendrimecurcumin nanoparticles. (A) Transmission electron microscopic images of the curcumin nanoformulations (1 mg/mL) before and after incubation with human serum 
albumin 100 µg. Incubation with human serum albumin was performed for 2 hours, after which the nanoparticles were deposited on transmission electron microscopy grids, 
stained with uranyl acetate, and imaged under transmission electron microscopy. red arrows represent uranyl acetate over stain. Blue arrows indicate aliened hsA networks. 
(B–C) change in particle size and zeta potential of curcumin nanoformulations before and after incubation with human serum albumin. Particle size was measured for 
3 minutes and the zeta potential was measured for 90 runs (9 minutes). 
Note: Data are reported as the mean ± standard error of the mean for three repeats for each incubation. 
Abbreviations: cD, β-cyclodextrin; cUr, curcumin; PLgA, polylactic-co-glycolic acid; hsA, human serum albumin.
grain size, as seen in the transmission electron microscopy 
study. A similar phenomenon was observed when nanopar-
ticles were incubated with HSA, bovine serum albumin, or 
Tween 80 dispersions.53 However, we observed little change 
in the zeta potential of the curcumin nanoformulations after 
adsorption of HSA   (Figure 2C). The zeta potential values for 
the curcumin PLGA, β-cyclodextrin, and nanogel formula-
tions were −7.71, −0.41, and −1.46 mV , and the values for 
their HSA complexes further decreased to −28.86, −27.63, 
and −7.28 mV , respectively. HSA-adsorbed molecules carry a 
net negative charge in   aqueous solution, resulting in a lowered 
negative zeta potential.55 No significant change was observed 
in the zeta potential values of the cellulose and dendrimer 
curcumin nanoformulations after HSA complexation. This 
could be possible because a HSA corona was not formed, 
HSA was loosely bound on the surface of the nanoparticles, 
or because HSA polymer chains were dispersed throughout 
the nanoformulations.
Interaction of curcumin nanoparticles 
with human serum proteins
Chemotherapeutic drug nanoformulations intended for 
human applications need to be evaluated for their impact 
on the immune system.56–58 Some nanoparticles can escape 
the phagocytosis process but may have a tendency to bind 
to serum proteins which disturb native immunity. To avoid 
this problem, selection of nanoformulations must be based on 
minimal interaction with serum proteins. Low protein-binding 
nanoformulations may carry and deliver drug molecules to 
target site(s) for an extended period. On the other hand, higher 
protein binding may lead to aggregation of nanoformulations 
over time, that allows elimination from the body. In this study, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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we evaluated the adsorption of protein onto curcumin nano-
particles, which varies according to the type of plasma protein 
(Figure 3A). Fibrinogen and immunoglobulin G adsorption is 
very low, while transferrin and HSA adsorption is very high. 
The decreasing degree of protein adsorption to nanoparticles 
is HSA . transferrin . immunoglobulin G . fibrinogen. 
However, it is evident that dendrimer curcumin nanopar-
ticles adsorbed more proteins compared with other types of 
curcumin nanoparticles. This suggests a higher degree of 
association/interaction of plasma proteins with the dendrimer 
curcumin nanoformulation which may not be appropriate for 
in vivo therapeutics. Densitometry quantification revealed 
that the order of adsorption of proteins to the different cur-
cumin nanoformulations was dendrimer . β-cyclodextrin . 
cellulose . nanogel . PLGA (Figure 3B). A 3.0–3.5-fold 
increase in protein adsorption was found with dendrimer 
curcumin nanoparticles compared with PLGA curcumin 
nanoparticles. A similar pattern of binding was observed for 
all curcumin nanoformulations incubated with bovine serum 
albumin (data not shown).
Chambers and Mitragotri reported that nanoparticles 
attached to the surface of red blood cells can dramatically 
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Figure 3 human serum proteins binding to curcumin nanoformulations (PLgA, β-cyclodextrin, cellulose, nanogel, and dendrimer). (A) sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis of curcumin nanoformulations (20 µM) incubated in 100 µg human plasma proteins (fibrinogen, immunoglobulin G, transferrin, and serum albumin). After 
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repeats for each incubation (mean ± standard error of the mean, *P , 0.05, compared with PLgA curcumin nanoformulation). (C) Adsorption of curcumin nanoparticles on 
red blood cells using different concentrations of curcumin nanoformulations (10–40 µM). 
Notes: Data are reported as the mean of three repeats for each adsorption (mean ± standard error of the mean deviation, *P , 0.05, compared with free curcumin or 
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improve their in vivo circulation characteristics.59 Unlike 
particle-protein complexes, particles adhered on red blood 
cells or red blood cell mimic nanoparticles remain in the 
blood circulation unless there are large shear forces and 
cell–cell interactions. Therefore, we investigated the adhe-
sion properties of curcumin particles in whole human blood. 
The adhesion process occurred after nanoparticles had 
interacted with plasma proteins in the blood. Adhesion of 
curcumin nanoparticles on red blood cells was determined 
by curcumin fluorescence using flow cytometry in channel 1 
(488   excitation, blue laser, 530 ± 15 nm, fluorescein isothio-
cyanate/green fluorescent protein, Figure 3C). The order of 
adhered curcumin nanoparticles on red blood cells was found 
to be PLGA . nanogel . β-cyclodextrin . cellulose . den-
drimer curcumin nanoformulations. The dendrimer exhibited 
very low adherence on red blood cells due to strong binding 
with plasma proteins, findings which are consistent with the 
above protein study.
From this study, our understanding is that both PLGA and 
nanogel curcumin nanoparticle interactions are minimal with 
both plasma proteins alone and in the presence of whole blood. 
Therefore, these formulations may be used for future in vivo 
and human clinical trials after detailed toxicological studies.
hemolysis
Hemolysis is a type of acute toxicity assay used to evaluate 
the hemocompatibility of the nanomaterials and to detect 
hemolyzation of erythrocytes.60–63 To assess the in vivo 
utility of a nanoformulation as a carrier for curcumin, the 
hemolytic potential in human blood needs to be tested.64,65 
Therefore, we evaluated a direct nanoparticle-erythrocyte 
membrane interaction in which the extent of disruption of the 
erythrocyte membrane was a direct measure of nanoparticle 
toxicity (Figure 4). The dark brown/red color (Figure 4A) 
signifies toxicity to red blood cells at those concentrations. 
The mechanism of red blood cell disruption depends entirely 
on the physical and chemical nature of the nanoformulations. 
Red blood cells treated with PLGA, β-cyclodextrin, cel-
lulose, and nanogel curcumin nanoformulations showed no 
signs of hemolysis at any concentration tested (Figure 4B). 
This behavior is very similar to that of the negative control 
treatment (Figure 4B). The dendrimer curcumin nanoformu-
lation did not show signs of hemolysis up to 100 µM, but 
after that, extreme dose-dependent hemolytic activity was 
observed (Figure 4B). Hemolysis is a rapid process and is 
likely due to binding with the negatively charged red blood 
cell membrane and its disturbance. This formulation demon-
strated hemolysis equivalent to that of the positive control, 
suggesting that serious toxicity would occur in vivo. The 
extensive hemolysis of the dendrimer curcumin formulation 
results from the   positively charged amino surface groups 
which are highly likely to destabilize the cell membrane 
and cause cell lysis.66 This type of lytic effect on red blood 
cells is extremely dangerous when administered in vivo, and 
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Figure 4 hemolysis of curcumin nanoformulations incubated in red blood cells. (A) Optical image of supernatants from hemolysis study. hemolysis was performed by incubating 
curcumin nanoformulations in red blood cells for two hours, centrifuging and collecting the supernatant for analysis. Phosphate-buffered solution and sodium dodecyl sulfate were 
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therefore polyethylene glycol (PEG) conjugation or PEGyla-
tion of dendrimer formulations may be required to decrease 
this activity.67
Red blood cells exposed to curcumin nanoformulations 
as well as negative and positive hemolysis-inducing agents 
were analyzed for morphological variations providing visual 
evidence of hemolysis (Figure 5). Untreated red blood cells 
(negative control) have a normal biconcave shape with no 
visible surface abnormalities, whereas a positive hemolytic 
agent (sodium dodecyl sulfate) exposed to red blood cells 
clearly exhibits ghost cell morphology with numerous sur-
face projections (Figure 5A). At low concentrations of all 
five curcumin nanoformulations (50 µM), exposure did not 
show aberrant morphological variations (Figure 5B), imply-
ing that hemolytic activity was not present. There were no 
morphological alterations observed, even in red blood cells 
treated with 100 µM of PLGA, β-cyclodextrin, cellulose, 
and nanogel curcumin nanoformulation, and no toxic effects 
were apparent (Figure 5C). However, a significant change 
in morphology and loss of biconcavity was observed when 
red blood cells were treated with the dendrimer curcumin 
nanoformulation, suggesting an increase in ghost cells and 
heavy hemolysis. This may be due to a higher rate of interac-
tion or penetration of the dendrimer nanoparticles through 
the membranes of the red blood cells.68,69 This behavior is 
attributable to either direct interaction with enzymes or a 
change in ATPase activity by the dendrimer formulation.70 
This activity may also depend on the type of dendrimer 
generated.71
Nanoparticle interactions with erythrocytes cause abnormal 
membrane proteins and lipids that lead to the destruction of 
erythrocyte integrity and hemolysis. To investigate why some 
curcumin formulations are toxic to erythrocytes at 100 µM, 
binding of nanoparticles and red blood cells was investigated 
using transmission electron microscopy.   Nanoparticles can 
usually be internalized within cancer cells as well as by many 
other primary cells. However, in this study, all the curcumin 
nanoformulations failed to   internalize in erythrocytes but 
instead attached to the membranes of the red blood cells 
(Figure 6). There were few PLGA, β-cyclodextrin, cellulose, 
or nanogel curcumin molecules on the membranes of 
erythrocytes (Figure 6, black arrows) compared with controls 
(Figure 6). A change in the morphology of the red blood cells 
from concave to spherical was observed, and secretion of 
some membrane proteins due to a higher rate of interaction 
with dendrimer curcumin nanoformulations (represented by 
squares) implies increased toxicity. This mainly occurs as a 
result of   interaction between the dendrimer and the protein 
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Figure 5 Morphological variation of red blood cells incubated with curcumin nanoformulations for 2 hours. Phase contrast images of red blood cells incubated with (A) controls 
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components of the plasma membrane, causing a change in 
the properties of the red blood cell membrane.71
Altogether, these results provide an interesting insight into 
the correlation between various curcumin nanoformulations 
and protein interactions that may impact in vivo efficacy. From 
the analysis of protein binding and hemolysis experiments, 
it can be concluded that all the curcumin nanoformulations 
behave differently than the dendrimer curcumin formulation. 
Our study clearly suggests that PLGA-based and nanogel-
based curcumin formulations have lower protein binding, 
with no signs of hemolysis, demonstrating their suitability for 
therapeutic application. In vivo studies of PLGA and polyNI-
PAM nanogel curcumin formulations have shown improved 
bioavailability, and therefore are more effective systems for 
delivering curcumin into tumors.12,14,16,72,73 These data clearly 
support the overall conclusion of this study. Our future 
research efforts will include evaluation of the in vivo pharma-
cokinetics of these curcumin nanoformulations to clarify the 
underlying mechanisms for potential cancer therapeutics.
Conclusion
This work underlines the importance of selection of efficient 
curcumin nanoformulations for biomedical applications, in 
particular for cancer therapeutics. The selection process is 
based on assessing the interaction or binding of nanoformula-
tions with common human blood proteins and erythrocytes. 
Overall, the study results indicate that PLGA and nanogel 
curcumin nanoformulations have lower interaction(s) with 
proteins and red blood cells and may predict better efficiency 
for in vivo therapeutic targets compared with other curcumin 
nanoformulations. Further, we believe that antibody-guided 
therapies using these curcumin formulations may be very 
useful for targeted tumor therapy and could replace conven-
tional chemotherapeutics in the future.
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